Maria Walz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maria Walz has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Agnes Lindenthal
University of Freiburg 1 Institute of Molecular Medicine and Cell Research (IMMZ), Faculty of Medicine Freiburg, Germany
29 shared publications - Alina Seger
University of Freiburg 1 Institute of Molecular Medicine and Cell Research (IMMZ), Faculty of Medicine Freiburg, Germany
29 shared publications Ariane Metzger
29 shared publications- Célia Asdih
University of Freiburg 1 Institute of Molecular Medicine and Cell Research (IMMZ), Faculty of Medicine Freiburg, Germany
29 shared publications - Ian James Frew
Department of Internal Medicine I, Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, Medical Center - University of Freiburg, Freiburg, Germany
29 shared publications - Jasmin Traichel
University of Freiburg 1 Institute of Molecular Medicine and Cell Research (IMMZ), Faculty of Medicine Freiburg, Germany
29 shared publications
Latest Publications
- Open Access
- 16 February 2026
- Published by American Association for Cancer Research (AACR)
Data from Novel Syngeneic Cell Lines for Studying High-Risk BRAFV600E-Driven Colorectal Cancer In Vivo
Combining anti-EGFR antibodies with BRAF/MEK/ERK pathway blockade opened new treatment options for BRAFV600E-driven colorectal cancer. Nevertheless, responses of these poor prognostic cancers are short-lived and heterogeneous, thereby highlighting the unmet need for novel concepts integrating targeted therapy and immuno-oncology. To this end, an immunocompetent mouse model with reliable disease onset and responding to clinically relevant drugs is essential but unavailable. In this study, we generated three cell lines from peritoneal metastases originating from orthotopically transplanted organoids carrying BrafV600E, Trp53R172H, and Apc mutations and characterized their ground state and responses to targeted therapy compounds in detail by RNA sequencing, whole-exome sequencing, and various functional assays. Interestingly, these so-called NaJa lines displayed distinct differentiation states and responses to the clinically relevant RAF inhibitors (RAFi) encorafenib and exarafenib, thereby resembling the clinical heterogeneity of BRAFV600E-driven colorectal cancer. RAFi resistance was overcome by the EGFR family inhibitor afatinib. RAFis also influenced the expression of the antigen presentation machinery, cytokines, and other immunomodulatory factors. Upon retransplantation into syngeneic mice, all NaJa lines established aggressive tumors with distinct tumor microenvironments matching their differentiation states. Thus, the NaJa lines provide a unique tool to study tumor heterogeneity, drug resistance, and the interplay between tumor, stroma, and immune cells in BRAFV600E-driven colorectal cancer.Significance:We present three newly isolated syngeneic BRAFV600E-driven colorectal cancer cell lines with distinct in vitro and in vivo phenotypes. They differ in their response to drug treatments, resemble patient tumor heterogeneity, and enable efficient tumor growth in immunocompetent mice for tumor-immune microenvironment studies.
- 16 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Novel Syngeneic Cell Lines for Studying High-Risk BRAFV600E-Driven Colorectal Cancer In Vivo
Combining anti-EGFR antibodies with BRAF/MEK/ERK pathway blockade opened new treatment options for BRAFV600E-driven colorectal cancer. Nevertheless, responses of these poor prognostic cancers are short-lived and heterogeneous, thereby highlighting the unmet need for novel concepts integrating targeted therapy and immuno-oncology. To this end, an immunocompetent mouse model with reliable disease onset and responding to clinically relevant drugs is essential but unavailable. In this study, we generated three cell lines from peritoneal metastases originating from orthotopically transplanted organoids carrying BrafV600E, Trp53R172H, and Apc mutations and characterized their ground state and responses to targeted therapy compounds in detail by RNA sequencing, whole-exome sequencing, and various functional assays. Interestingly, these so-called NaJa lines displayed distinct differentiation states and responses to the clinically relevant RAF inhibitors (RAFi) encorafenib and exarafenib, thereby resembling the clinical heterogeneity of BRAFV600E-driven colorectal cancer. RAFi resistance was overcome by the EGFR family inhibitor afatinib. RAFis also influenced the expression of the antigen presentation machinery, cytokines, and other immunomodulatory factors. Upon retransplantation into syngeneic mice, all NaJa lines established aggressive tumors with distinct tumor microenvironments matching their differentiation states. Thus, the NaJa lines provide a unique tool to study tumor heterogeneity, drug resistance, and the interplay between tumor, stroma, and immune cells in BRAFV600E-driven colorectal cancer.Significance:We present three newly isolated syngeneic BRAFV600E-driven colorectal cancer cell lines with distinct in vitro and in vivo phenotypes. They differ in their response to drug treatments, resemble patient tumor heterogeneity, and enable efficient tumor growth in immunocompetent mice for tumor-immune microenvironment studies.
- Open Access
- 16 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Novel Syngeneic Cell Lines for Studying High-Risk BRAFV600E-Driven Colorectal Cancer In Vivo
- 16 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Novel Syngeneic Cell Lines for Studying High-Risk BRAFV600E-Driven Colorectal Cancer In Vivo
- Open Access
- 16 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Novel Syngeneic Cell Lines for Studying High-Risk BRAFV600E-Driven Colorectal Cancer In Vivo
Source data (uncropped blots and tables with individual data points) provided as a single Excel file
- 16 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Novel Syngeneic Cell Lines for Studying High-Risk BRAFV600E-Driven Colorectal Cancer In Vivo
Source data (uncropped blots and tables with individual data points) provided as a single Excel file
- Open Access
- 16 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Novel Syngeneic Cell Lines for Studying High-Risk BRAFV600E-Driven Colorectal Cancer In Vivo
Supplementary Figure S5 shows a Circos plot of the whole-exome sequencing data from NaJa cells and their donor organoid.
- 16 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Novel Syngeneic Cell Lines for Studying High-Risk BRAFV600E-Driven Colorectal Cancer In Vivo
Supplementary Figure S5 shows a Circos plot of the whole-exome sequencing data from NaJa cells and their donor organoid.
- Open Access
- 16 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Novel Syngeneic Cell Lines for Studying High-Risk BRAFV600E-Driven Colorectal Cancer In Vivo
Supplementary Figure S8 shows comparisons of the baseline transcriptome of NaJa cells, as well as a Western blot of baseline phospho-AKT expression.
- 16 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Novel Syngeneic Cell Lines for Studying High-Risk BRAFV600E-Driven Colorectal Cancer In Vivo
Supplementary Figure S8 shows comparisons of the baseline transcriptome of NaJa cells, as well as a Western blot of baseline phospho-AKT expression.
- Open Access
- 16 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Novel Syngeneic Cell Lines for Studying High-Risk BRAFV600E-Driven Colorectal Cancer In Vivo
Table S3. Apoptosis hallmark genes in RNA-seq of encorafenib-treated NaJa cells
- 16 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Novel Syngeneic Cell Lines for Studying High-Risk BRAFV600E-Driven Colorectal Cancer In Vivo
Table S3. Apoptosis hallmark genes in RNA-seq of encorafenib-treated NaJa cells
- Open Access
- 16 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Novel Syngeneic Cell Lines for Studying High-Risk BRAFV600E-Driven Colorectal Cancer In Vivo
Supplementary Figure S3 shows the take rate of orthotopic transplantation of BPAC organoids, PCR confirmation of tumor origin and H&E and IHC images of tumors and metastases.
- 16 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Novel Syngeneic Cell Lines for Studying High-Risk BRAFV600E-Driven Colorectal Cancer In Vivo
Supplementary Figure S3 shows the take rate of orthotopic transplantation of BPAC organoids, PCR confirmation of tumor origin and H&E and IHC images of tumors and metastases.
- Open Access
- 16 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Novel Syngeneic Cell Lines for Studying High-Risk BRAFV600E-Driven Colorectal Cancer In Vivo
Table S4. Relative expression of PD-L2 (Pdcdc1lg2) in RNA-seq of encorafenib-treated NaJa cells
- 16 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Novel Syngeneic Cell Lines for Studying High-Risk BRAFV600E-Driven Colorectal Cancer In Vivo
Table S4. Relative expression of PD-L2 (Pdcdc1lg2) in RNA-seq of encorafenib-treated NaJa cells
- Open Access
- 16 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11 from Novel Syngeneic Cell Lines for Studying High-Risk BRAFV600E-Driven Colorectal Cancer In Vivo
Supplementary Figure S11 shows images of NaJa cell–induced tumor growth outside the liver.
- 16 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11 from Novel Syngeneic Cell Lines for Studying High-Risk BRAFV600E-Driven Colorectal Cancer In Vivo
Supplementary Figure S11 shows images of NaJa cell–induced tumor growth outside the liver.
- Open Access
- 16 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Novel Syngeneic Cell Lines for Studying High-Risk BRAFV600E-Driven Colorectal Cancer In Vivo
Supplementary Figure S9 shows the induction of apoptosis hallmark transcripts following encorafenib treatment and a drug washout colony formation assay after encorafenib and afatinib treatment of NaJa cells.
- 16 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Novel Syngeneic Cell Lines for Studying High-Risk BRAFV600E-Driven Colorectal Cancer In Vivo
Supplementary Figure S9 shows the induction of apoptosis hallmark transcripts following encorafenib treatment and a drug washout colony formation assay after encorafenib and afatinib treatment of NaJa cells.